A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

NCT02927873 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSV (GSK3389245A) low dose formulation vaccine
BIOLOGICAL: RSV (GSK3389245A) middle dose formulation vaccine
BIOLOGICAL: RSV (GSK3389245A) high dose formulation vaccine
DRUG: Placebo

Sponsor

GlaxoSmithKline